



**Institute of Kidney
Lifescience Technologies**

The Evolution of GFR Estimation: An update as of December 2021

Tabo Sikaneta, MD FRCPC


Nephrologist, The Scarborough Health Network



**Institute of Kidney
Lifescience Technologies**


What is the Glomerular Filtration Rate (GFR) and why do we care about it?

- GFR is the volume of plasma filtered through the glomeruli per unit time
- The kidneys perform their myriad tasks on this filtrate
- Reflects the total number of functioning glomeruli and is therefore the best way to assess kidney function in health and disease



$$\text{Excretion} = \text{Filtration} - \text{Reabsorption} + \text{Secretion}$$

Stages of Kidney Disease



GFR, glomerular filtration rate


The GFR has many uses...

- To define CKD (less than 60 ml/min for 3 months)
- To stage CKD (e.g., 59–45, 44–30, 29–15, <15 ml/min)
- To monitor rates of progression of CKD
- To dose adjust medications and make other treatment decisions
- To prognosticate outcomes in patients with CKD
- It is the primary indicator of renal function used in clinical practice guidelines (e.g. the National Kidney Foundation's Kidney Disease Quality Initiative (K/DOQI) clinical practice guidelines)

Stage of Kidney Disease NKDEP Classification

Normal	Healthy kidneys GFR > 90 mL/min per 1.73 m ²
Stage 1	Kidney damage with normal or elevated GFR GFR > 90 mL/min per 1.73 m ²
Stage 2	Kidney damage and mild decrease in GFR GFR of 60 - 89 mL/min per 1.73 m ²
Stage 3 a/b	Moderate decrease in GFR GFR of 30-44 / 45-59 mL/min per 1.73 m ²
Stage 4	Severe decrease in GFR GFR 15 - 29 mL/min per 1.73 m ²
Stage 5	Kidney failure - ESRD GFR of <15 mL/min per 1.73 m ²

GFR vs solute clearance



$$\text{Excretion} = \text{Filtration} - \text{Reabsorption} + \text{Secretion}$$

Solute Clearance

- GFR is indirectly measured by the volume of plasma that is cleared of an ideal solute by the kidneys per unit time
- Ideal solutes have a constant rate of appearance in the blood, are freely filtered by the glomerulus, and are neither reabsorbed nor secreted by the tubules
- The only ideal solutes are exogenous and administered in a research setting (e.g., inulin and ¹²⁵I-iothalamate)
- Creatinine clearance is the most widely used endogenous solute clearance, but is not ideal as creatinine does not have a constant rate of appearance (e.g., reduced in muscle wasting states), and is secreted by the proximal tubule
- Cystatin represents another endogenous solute that is renally-cleared* and which has a more constant rate of appearance

Cystatin C as a GFR Marker

- Cystatin C is a small 13 kDa protein that is a member of the cysteine proteinase inhibitor family that is produced at a constant rate by all nucleated cells
- Due to its small size & positive charge at physiological pH, it is freely filtered by the glomerulus, and is not secreted but is fully reabsorbed and catabolized in proximal renal tubules
- This means the primary determinant of blood Cystatin C levels is the rate at which it is filtered at the glomerulus making it an excellent GFR marker
- **Normal serum Cystatin C values range from 0.6 to 1.0 mg/L**

Cystatin C as a GFR Marker

- Unlike creatinine, Cystatin C serum levels are virtually unaffected by age (>1 yr), muscle mass, gender, and race
- A number of very simple formulas have been introduced which can be used to obtain an estimated GFR using Cystatin C
- Multiple studies have found Cystatin C to be more sensitive to actual changes in GFR in the early stages of CKD than creatinine based GFR estimates
- A significant advantage of Cystatin C based formulas, unlike creatinine-based equations, is that Cystatin C based estimated GFR formulas are not biased according to GFR and there is no **GFR blind area** with Cystatin C

Cystatin C & Stages of CKD



Measured Versus Estimated GFR

Measurements of GFR are:

- Time consuming
- Cumbersome
- Expensive
(especially for exogenous solute clearance assays)
- Restricted

- Estimations of GFR are designed to be:
 - Quick
 - Easy
 - Affordable
 - Widely available
- Based on serum concentrations of endogenous solutes (such as creatinine and cystatin)

Challenges with GFR Estimation

- Based on endogenous solutes and their inherent limitations
- Creatinine, which is produced by muscle, varies according to race, sex, and age in GFR-independent ways
- Cystatin, which is produced by all nucleated cells, is increased in high-turnover states, use of corticosteroids, and in hyperthyroidism
- GFR estimation equations should ideally be useful across the spectrum of GFR (i.e., no inaccuracies or **blind spots** at any point in this continuum), and across all populations/demographics



Key Developments in the Evolution of GFR Estimation

- Came from studies that derived equations for GFR's that predicted measured GFR's
 - Cockcroft-Gault 1976 (249 males, measured GFR used non-standardized creatinine)
 - MDRD 1999 (840 patients with CKD, measured GFR used exogeneous solute)
 - CKD-EPI creat 2009 (8,254 participants with and without CKD)
 - CKD-EPI cystatin and creat-cystatin 2012 (5,352 participants with and without CKD)
 - CKD-EPI creat, cystatin, creat-cyst 2021 (4,050 participants with and without CKD)

The Cockcroft-Gault Equation

**Calculation of estimated creatinine clearance (ml/min)
according to the Cockcroft-Gault equation =**

$$\frac{[140 - \text{age (years)}] \times \text{ideal weight (kg)}}{[\text{serum creatinine (mg/dl)}] \times 72} \times 0.85 \text{ if female}$$

The Modification of Diet in Renal Disease (MDRD) Equation

MDRD estimated creatinine clearance (ml/min/1.73m²) =

$$175 \times [\text{serum creatinine (mg/dl)}]^{-1.154} \times [\text{age (years)}]^{-0.203} \times [0.742 \text{ if female}] \times [1.21 \text{ if black}]$$



The CKD-EPI Consortium

“The CKD Epidemiology Collaboration (CKD-EPI) is a research group with major interests in measurement and estimation of GFR (CKD-EPI GFR)”

**CKD-EPI estimated creatinine clearance
(ml/min/1.73m²) =**

$$141 \times \min[\text{SCr (mg/dl)/kappa}, 1]^\alpha \times \max[\text{SCr (mg/dl)/K}, 1]^{-0.209} \times 0.993^{\text{Age}} \times \text{Sex} \times \text{Race}$$

For female: Sex=1.018; alpha=-0.329; kappa=0.7

For male: Sex=1; alpha=-0.411; kappa=0.9

**CKD-EPI cystatin C equation
(ml/min/1.73m²) =**

$$133 \times \min[\text{Scys}/0.8, 1)^{-0.499} \times \max [\text{Scys}/0.8, 1)^{-1.328} \times 0.996^{\text{Age}} \times 0.932 \text{ if female}$$

CKD-EPI, CKD Epidemiology Collaboration; GFR, glomerular filtration rate

1. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.
2. Inker LA, Eckfeldt J, Levey AS, et al. Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. *Am J Kidney Dis* 2011;58:682-4.



CKD EPI: Creatinine + Cystatin C Equation (2012)

“Combined creatinine–cystatin C equations perform better than equations based on either of these markers alone”

CKD-EPI creatinine–cystatin C equation (ml/min/1.73m²) =

$$135 \times \min[\text{SCr (mg/dl)/}\kappa, 1]^\alpha \times \max[\text{SCr (mg/dl)/}\kappa, 1]^{-0.601} \times \min[\text{SCys/0.8}, 1]^{-0.375} \\ \times \max[\text{SCys/0.8}, 1]^{-0.711} \times 0.995^{\text{Age}} \times 0.969 \text{ if female} \times 1.08 \text{ if Black}$$

For female: alpha=-0.248; kappa=0.7

For male: Sex=1; alpha=-0.207; kappa=0.09

Revised CKD-EPI Creatinine + Cystatin C Equation (2021)

“New eGFR equations that incorporate creatinine and cystatin C but omit race are more accurate and lead to smaller differences between Black participants and non-Black participants than new equations without race with either creatinine or cystatin C alone”

Gender	Scr (mg/dL)	Scys (mg/L)	Equation (mL/min/1.73 m ²)
Female	≤0.7	≤0.8	$130 \times (\text{Scr}/0.7)^{-0.248} \times (\text{Scys}/0.8)^{-0.375} \times 0.995^{\text{age}}$
		>0.8	$130 \times (\text{Scr}/0.7)^{-0.248} \times (\text{Scys}/0.8)^{-0.711} \times 0.995^{\text{age}}$
	>0.7	≤0.8	$130 \times (\text{Scr}/0.7)^{-0.601} \times (\text{Scys}/0.8)^{-0.375} \times 0.995^{\text{age}}$
		>0.8	$130 \times (\text{Scr}/0.7)^{-0.601} \times (\text{Scys}/0.8)^{-0.711} \times 0.995^{\text{age}}$
Male	≤0.9	≤0.8	$135 \times (\text{Scr}/0.9)^{-0.207} \times (\text{Scys}/0.8)^{-0.375} \times 0.995^{\text{age}}$
		>0.8	$135 \times (\text{Scr}/0.9)^{-0.207} \times (\text{Scys}/0.8)^{-0.711} \times 0.995^{\text{age}}$
	>0.9	≤0.8	$135 \times (\text{Scr}/0.9)^{-0.601} \times (\text{Scys}/0.8)^{-0.375} \times 0.995^{\text{age}}$
		>0.8	$135 \times (\text{Scr}/0.9)^{-0.601} \times (\text{Scys}/0.8)^{-0.711} \times 0.995^{\text{age}}$

Summary Timeline

1973

Cockcroft-Gault

1999

MDRD

2009

CKD-EPI creatinine 2009

2012

CKD-EPI cystatin
CKD-EPI creatinine +
cystatin

2021

Revised CKD-EPI
creatinine + cystatin - race



Remaining Challenges

- Translating the latest findings into clinical practice here in Ontario
- Getting laboratories to incorporate these findings into their reports
- Educating other healthcare providers about these advances in order to streamline referral and management practices